Equities

Helix BioMedix Inc

HXBM:PKL

Helix BioMedix Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)15.35
  • Today's Change0.00 / 0.00%
  • Shares traded320.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 31 2024 18:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Helix BioMedix Inc grew revenues 122.07% from 851.68k to 1.89m while net income improved from a loss of 7.71m to a smaller loss of 2.49m.
Gross margin68.96%
Net profit margin-125.06%
Operating margin-117.30%
Return on assets-100.64%
Return on equity-122.53%
Return on investment-120.73%
More ▼

Cash flow in USDView more

In 2011, cash reserves at Helix BioMedix Inc fell by 2.36m. Cash Flow from Financing was even, which indicates that this company's capital needs are balanced. In addition the company used 2.30m for operations while cash used for investing totalled 59.32k.
Cash flow per share-15.03
Price/Cash flow per share--
Book value per share6.95
Tangible book value per share6.37
More ▼

Balance sheet in USDView more

Helix BioMedix Inc appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio2.33
Quick ratio1.69
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.